Respiratory distress syndrome (RDS) remains a significant concern in neonatology, primarily associated with preterm deliveries. Surfactant insufficiency leads to alveolar collapse, impaired gas exchange, and subsequent respiratory failure if untreated. Historically, surfactant replacement therapy has demonstrated remarkable efficacy in very preterm infants born before 32 weeks of gestation. However, the benefits and implications of surfactant use in infants born between 34 and 38 weeks gestational age—classified as late preterm to early term—have been less clear, prompting the need for detailed investigation.

The research conducted by Peterson, Hassen, Avila Misciagno, and their colleagues rigorously evaluates a cohort of infants fitting this late preterm to early term profile who were diagnosed with respiratory distress. Their methodology entailed a comprehensive review of clinical outcomes following surfactant administration, contrasting them with those who managed respiratory distress without surfactant therapy. The study’s premise focused on whether surfactant therapy could shorten hospital stays or reduce dependency on respiratory support modalities such as CPAP and mechanical ventilation in this group.

Findings indicate a nuanced response to surfactant therapy. The administration of surfactant in late preterm and early term infants with respiratory distress was linked to a statistically significant reduction in the duration of mechanical ventilation. This observation is clinically pivotal as it signifies reduced exposure to invasive respiratory strategies and their associated risks, including ventilator-induced lung injury and infection. Reduced reliance on mechanical ventilation also suggests improved lung compliance and gas exchange efficiency afforded by surfactant replacement even beyond the traditionally defined preterm window.

Despite these promising findings concerning mechanical ventilation, the impact of surfactant therapy on CPAP usage was less pronounced. The data revealed that the duration for which infants were supported on CPAP did not significantly differ whether surfactant was administered or not. This suggests that surfactant’s principal benefit manifests in infants requiring invasive support rather than those with milder respiratory distress managed with non-invasive ventilation strategies.

One of the more intriguing aspects of the study relates to the length of hospital stay (LOS). Surfactant use did not correlate with a reduction in LOS overall. This finding challenges earlier assumptions that improved respiratory function inherently shortens hospitalization. The complexity of postnatal developmental care, feeding establishment, and other neonatal morbidities likely interplay in determining hospital duration, independent of respiratory intervention efficacy. The lack of LOS reduction invites a broader consideration of multidisciplinary strategies to optimize overall neonatal outcomes.

The researchers delve into the pathophysiological rationale explaining why surfactant replacement might yield differential benefits across the spectrum of respiratory supports. In infants necessitating mechanical ventilation, surfactant effectively enhances alveolar stability, directly addressing hyaline membrane pathology. Conversely, CPAP-supported infants might inherently possess milder surfactant deficiencies or better endogenous surfactant function, moderating the observable clinical impact of exogenous surfactant.

This investigation also underscores the importance of accurate respiratory distress diagnosis and careful stratification of infants who truly benefit from surfactant therapy. Late preterm and early term infants often present with a heterogeneous clinical phenotype—transient tachypnea, delayed clearance of fetal lung fluid, or surfactant deficiency-related problems intermingle. This heterogeneity may explain varied treatment responses and emphasizes the need for more predictive biomarkers or imaging techniques to guide targeted surfactant use.

Moreover, the study’s large sample size and robust analytical framework enhance the credibility of the findings, offering neonatologists evidence-based guidelines to refine surfactant administration protocols. It advocates for a more individualized approach, utilizing surfactant selectively in infants with confirmed surfactant deficiency manifesting severe respiratory distress sufficiently intense to warrant mechanical ventilation.

The implications for clinical practice extend to potentially rethinking prophylactic versus rescue surfactant strategies. While prophylactic surfactant administration remains standard in very preterm infants, this research highlights rescue therapy tailored to clinical severity as a viable strategy in late preterm and early term infants. Such a pragmatic approach could optimize resource utilization and minimize unnecessary interventions.

From a mechanistic viewpoint, surfactant administration’s role in mitigating inflammation and enhancing pulmonary compliance is reaffirmed. These attributes are particularly valuable in a population at risk for respiratory morbidity yet often overlooked in clinical trials focusing primarily on earlier gestational ages. The research prompts future trials to explore adjunctive therapies that complement surfactant’s effects.

Additionally, this study encourages further exploration of long-term neurodevelopmental outcomes associated with varied respiratory support strategies. While the focus was on short-term clinical endpoints, the interaction between early respiratory interventions and subsequent developmental trajectories remains a fertile ground for research, with surfactant therapy potentially playing a modulatory role.

In conclusion, this pivotal research invites a paradigm shift in neonatal respiratory care for late preterm to early term infants. Surfactant therapy emerges as a strategic tool rather than a ubiquitous treatment, significantly curtailing mechanical ventilation duration but without necessarily reducing CPAP dependence or length of hospital stay. The comprehensive evaluation deepens our understanding of respiratory management nuances, fostering precision medicine principles in neonatal care.

As neonatal survival rates improve globally, ensuring quality of care becomes paramount. This study acts as a catalyst for multidisciplinary teams to recalibrate respiratory distress management protocols, ensuring that surfactant therapy is judiciously employed where its benefits are maximized. It catalyzes a wave of clinical and translational research dedicated to optimizing care pathways for this vulnerable yet understudied group.

Expert commentary on this study highlights its potential to influence guidelines and clinical algorithms. Incorporation of these findings into protocols can reduce the retrospective variability in surfactant use, thereby avoiding overtreatment or undertreatment. Such evidence-based stewardship ultimately improves neonatal outcomes and resource efficiencies within neonatal intensive care units worldwide.

As the field advances, integration of artificial intelligence and machine learning may further refine the selection criteria for surfactant therapy in late preterm and early term infants. Predictive modeling of respiratory failure trajectories, informed by studies like these, could revolutionize neonatal respiratory care, marking a thrilling horizon in perinatal medicine.

Through its rigorous methodology, clinically relevant insights, and balanced interpretation, this research sets a new benchmark in neonatal respiratory therapeutics. Recognizing surfactant therapy’s selective benefits empowers clinicians to deliver personalized care that aligns with each infant’s unique respiratory profile and clinical course, heralding improved short-term outcomes in this intricate neonatal population.

Subject of Research: Evaluation of surfactant therapy and its effects on clinical outcomes including length of hospital stay, CPAP usage, and mechanical ventilation in late preterm to early term infants.

Article Title: Short-term outcomes associated with surfactant use in respiratory distress in late preterm to early term infants.

Article References:
Peterson, C., Hassen, K., Avila Misciagno, S. et al. Short-term outcomes associated with surfactant use in respiratory distress in late preterm to early term infants. J Perinatol (2026). https://doi.org/10.1038/s41372-026-02791-x

Image Credits: AI Generated

DOI: 01 July 2026

Late preterm infants, born between 34 and 36 weeks’ gestation, occupy a unique clinical space. Although more mature than their extremely preterm counterparts, they remain at heightened risk for respiratory complications, including respiratory distress syndrome (RDS). Unlike earlier preterm infants who suffer from surfactant deficiency due to incomplete lung development, the clinical heterogeneity in late preterms hinges on complex interactions involving lung maturity, inflammation, and variable surfactant production. This complexity has made the determination of suitable candidates for surfactant replacement therapy an intricate medical puzzle.

The study rigorously evaluates the biophysical properties of pulmonary surfactant within this subgroup, highlighting how alterations in surfactant composition and function contribute to respiratory compromise. Pulmonary surfactant, a lipid-protein complex, reduces alveolar surface tension, preventing collapse during exhalation and facilitating gas exchange. In late preterm infants, partial surfactant deficiency or dysfunction may arise from incomplete synthesis or biophysical inactivation, for instance due to inflammatory cytokines or infection. Identifying molecular and clinical markers indicative of such dysfunction is pivotal for clinical decision-making.

Jeffreys and Dassios employed advanced biomarker profiling and imaging techniques to delineate surfactant status. Their methodology integrated quantitative measurements of surfactant lipids, surface tension dynamics, and real-time lung ultrasound scores. Notably, these diagnostic approaches transcend conventional radiographic evaluations, offering a more sensitive and mechanistic insight into lung physiology. The data underscore that not all late preterm infants with respiratory distress share the same pathophysiological substrate, warranting stratified treatment interventions.

One of the most striking revelations of the study is the identification of a subset of late preterm infants who exhibit significant surfactant dysfunction despite relatively mature gestational age. This subgroup, characterized by elevated markers of alveolar inflammation and dysregulated surfactant protein expression, responded favorably to exogenous surfactant administration. Clinical outcomes included reduced ventilator dependency, shorter hospital stays, and diminished incidence of chronic lung disease, heralding a paradigm shift in treatment protocols.

This differentiation of surfactant dysfunction versus pure structural immaturity or other etiologies of respiratory distress allows clinicians to refine therapeutic indications. The study emphasizes that indiscriminate surfactant therapy in all late preterms with respiratory distress is neither cost-effective nor clinically justified. Instead, a precision medicine approach, leveraging individualized assessment and biomarker-guided therapy, promises to optimize outcomes while minimizing risks.

Mechanistically, the study elaborates on how surfactant supplementation restores alveolar mechanics by re-establishing surface tension homeostasis and attenuating inflammatory cascades. The anti-inflammatory properties of certain surfactant proteins, particularly SP-A and SP-D, may also contribute to modulating immune responses in the neonatal lung. This dual role — mechanical stability and immunomodulation — positions surfactant as a critical therapeutic agent in the delicate interplay of lung development and injury.

In the broader context of neonatal care, these findings intersect with advances in non-invasive respiratory support and neonatal intensive care unit (NICU) protocols. The ability to accurately identify candidates for surfactant replacement could reduce reliance on invasive ventilation strategies, thereby mitigating ventilator-associated lung injury. Moreover, timely intervention prior to progression of respiratory failure may curtail long-term morbidities, including bronchopulmonary dysplasia, which carry lifelong health implications.

Jeffreys and Dassios also highlight implications for healthcare systems, particularly in resource allocation and policy-making. Surfactant preparations are costly and require specialized delivery methods. By targeting therapy to infants with proven surfactant deficiency or dysfunction, hospitals can reduce unnecessary interventions and associated healthcare burdens. Furthermore, enhanced diagnostic capabilities foster a more judicious use of surfactant, aligning with principles of value-based care.

Future directions suggested by the study include the development of bedside assays for surfactant function and expanded research into genetic and environmental factors influencing surfactant metabolism in late preterm neonates. There is also a call for large-scale randomized controlled trials to validate biomarker-guided treatment models and to explore novel surfactant formulations with enhanced anti-inflammatory properties.

In summary, the research by Jeffreys and Dassios marks a transformative step in neonatal respiratory medicine. By dissecting the pathophysiology of late preterm respiratory disease and pinpointing candidates for surfactant replacement therapy, it paves the way for personalized interventions that promise better survival and quality of life for these infants. The study exemplifies the fusion of precision diagnostics, molecular biology, and clinical therapeutics in addressing complex neonatal conditions.

As neonatal care evolves, such insights emphasize the importance of tailored treatment strategies grounded in mechanistic understanding. The hope remains that future neonatal outcomes will be defined less by the challenges of prematurity and more by the efficacy of targeted, science-driven care.

Subject of Research: Surfactant replacement therapy in late preterm infants with respiratory disease, and the identification of suitable candidates for this therapy.

Article Title: Surfactant replacement therapy in late preterm respiratory disease: Identifying suitable candidates.

Article References:

Jeffreys, E., Dassios, T. Surfactant replacement therapy in late preterm respiratory disease: Identifying suitable candidates. Pediatr Res (2025). https://doi.org/10.1038/s41390-025-04705-7

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41390-025-04705-7